alexa Nanomedicine: Will it be able to Overcome Multidrug Resistance in Cancers? | OMICS International
ISSN: 2155-9864
Journal of Blood Disorders & Transfusion

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Nanomedicine: Will it be able to Overcome Multidrug Resistance in Cancers?

Sten Friberg*

Department of Neuroscience, Swedish Medical Nanoscience Center, Karolinska Institutet, Retzius väg, Stockholm, Sweden

*Corresponding Author:
Sten Friberg
Department of Neuroscience
Swedish Medical Nanoscience Center
Karolinska Institutet, Retzius väg 8
171 77, Stockholm, Sweden
+46 8 524 800 00
Email: [email protected]

Received date: September 09, 2016; Accepted date: September 15, 2016; Published date: September 19, 2016

Citation: Friberg S (2016) Nanomedicine: Will it be able to Overcome Multidrug Resistance in Cancers? J Blood Disord Transfus 7:368. doi:10.4172/2155-9864.1000368

Copyright: © 2016 Friberg S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Blood Disorders & Transfusion

At present, every third individual in the Western world is diagnosed with a cancer at some point in their lives. In spite of great advances in oncology in recent decades, around 50% of these individuals will die from their diseases. The great majority of these deaths are caused by cancer cells endowed with multiple drug resistance (MDR). These cells are not eliminated by present-day therapies, and new strategies for general oncologic treatment are needed. The shape of such new treatments is emerging, and such treatments will likely be highly individualized, but at the same time highly complex and costly.

Multimodality is mandatory, and the treatment steps will be sequential.

The plausible major steps are likely to be:

1. Blocking of the genes responsible for MDR,

2. Killing of the adult cancer cells that are protecting the malignant stem cells. With the genes blocked in Step 1, the adult cancer cells will be more susceptible to toxic drugs. This will allow smaller amounts of therapeutic drugs to be used, leading to fewer toxic side effects,

3. The dead adult cancer cells must be removed to expose the dormant cancer stem cells. Dormant cancer cells are believed to be unaffected by present-day oncologic therapies,

4. Initiation of proliferation among the cancer stem cells which will make them susceptible to education or killing,

5. Killing of the malignant stem cells, or educating them to enter permanent dormancy and thus render them harmless.

For these five steps, the medical profession is already in possession of most of the needed therapeutic agents. However, some of these agents are toxic when given intravenously in humans, and some of them are inactivated during the transport in the blood. Nanoparticles might offer a dual benefit by protecting the patient from the agent, and simultaneously protecting the agent from the patient.

What is lacking is knowledge of the time needed for each step and of the potential side effects for each step.

Effective targeting methods currently exist for superficial tumors (both primary and secondary), but not for deep-seated cancers.

A more detailed version of this summary is found in:”Nanomedicine: will it offer possibilities to overcome multiple drug resistance in cancer?” J Nanobiotechnology.

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 8296
  • [From(publication date):
    October-2016 - Jul 21, 2018]
  • Breakdown by view type
  • HTML page views : 8219
  • PDF downloads : 77

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version